Approximately 60–70% of all diagnosed breast cancers fall under the luminal A subtype, which is defined as ER-positive and/or PR-positive, HER2-negative, with low proliferative capacity by Ki67 IHC [1]. Here, ERBB2 is linked to breast cancer.